Morphological features of thyroid benign focal neoplasms in Graves’ disease

Authors

  • Yu.V. Buldygina State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-9219-2737
  • A.V. Zelinskaya State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-4320-6901
  • L.Yu. Zurnadzhy State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0001-5138-4532
  • Yu.M. Tarashchenko State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-4787-359X
  • S.L. Shlyakhtych 3rd Kyiv City Clinical Hospital, Kyiv, Ukraine Morphological features of thyroid benign focal neoplasms in Graves’ disease https://orcid.org/0000-0002-7784-8320
  • M.D. Tronko State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0001-7421-0981

DOI:

https://doi.org/10.22141/2224-0721.18.4.2022.1174

Keywords:

Graves’ disease, thyroid gland, benign thyroid neoplasms

Abstract

Background. The morphology of the thyroid in Graves’ disease (GD) can be quite diverse: in most cases there is a diffuse enlargement of the thyroid gland (diffuse goiter), in some cases it is not increased, and in some patients there are focal neoplasms (single and multiple), including thyroid cancer. According to some studies, in patients with Graves’ disease, focal formations are observed in 10–31% of cases, and in half of the patients, they appear against the background of treatment with thionamides. The purpose of this paper was a retrospective study of the morphological features of benign thyroid neoplasms due to GD based on the results of cytological and pathomorphological studies. Materials and methods. The study was performed at the clinic of the State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”. All patients with GD who were operated in the Department of Endocrine Surgery from 2008 to 2019 (1854 patients) were first selected, and then those who had benign focal formations according to the pathohistological examination were selected among them. Results. The frequency of benign thyroid neoplasms in GD is 22.06 % in women aged 26 to 55 years. Cytological studies of thyroid neoplasm punctures in GD made it possible to clearly establish their benign nature (BSRTC-2) in 94.3 % of cases. In 5.7 % of cases, cytological categories BSRTC-3 and BSRTC-4 were established. Positive immunocytochemical reactions to thyroid peroxidase and thyroglobulin, and the absence of CK17 allow avoiding cytological overdiagnosis, characteristic of benign neoplasms of the thyroid gland in GD. Conclusions. Among pathohistologically confirmed benign neoplasms of the thyroid gland in GD, in 63.82 % of cases a histological diagnosis was adenomatous or colloid goiter, in 34.47 % — signs of nodular hyperplasia, in 1.71 % — the presence of thyroiditis.

Downloads

Download data is not yet available.

References

Ehlers M, Schott M, Allelein S. Graves' disease in clinical perspective. Front Biosci (Landmark Ed). 2019;24(1):35-47. doi: 10.2741/4708.

Wiersinga WM. Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease. Endocrinol Metab (Seoul). 2016;31(2):213-22. doi: 10.3803/EnM.2016.31.2.213.

Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387. doi: 10.1016/j.beem.2020.101387.

Rapoport B, Aliesky HA, Chen CR, McLachlan SM. Evidence that TSH Receptor A-Subunit Multimers, Not Monomers, Drive Antibody Affinity Maturation in Graves' Disease. J Clin Endocrinol Metab. 2015;100(6):E871-5. doi: 10.1210/jc.2015-1528.

Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016;84(1):115-20. doi: 10.1111/cen.12688.

Lima PC, Moura Neto A, Tambascia MA, Zantut Wittmann DE. Risk factors associated with benign and malignant thyroid nodules in autoimmune thyroid diseases. ISRN Endocrinol. 2013;2013:673146. doi: 10.1155/2013/673146.

Staniforth JUL, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves' disease: A meta-analysis. Int J Surg. 2016;27:118-125. doi: 10.1016/j.ijsu.2015.11.027.

Casella C, Morandi R, Verrengia A, et al. Thyroid Cancer and Nodules in Graves' Disease: A Single Center Experience. Endocr Metab Immune Disord Drug Targets. 2021;21(11):2028-2034. doi: 10.2174/1871530321666201230111911.

Papanastasiou A, Sapalidis K, Goulis DG, et al. Thyroid nodules as a risk factor for thyroid cancer in patients with Graves' disease: A systematic review and meta-analysis of observational studies in surgically treated patients. Clin Endocrinol (Oxf). 2019;91(4):571-577. doi: 10.1111/cen.14069.

Khan SH, Rather TA, Makhdoomi R, Malik D. Nodular Graves' disease with medullary thyroid cancer. Indian J Nucl Med. 2015;30(4):341-4. doi: 10.4103/0972-3919.164022.

Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020;105(12):3704-20. doi: 10.1210/clinem/dgaa646.

Bolgov MYu. Healthcare Automation (966-8668-26-X). Kiev: Izdatelstvo Kupriyanov; 2006. 464 p. (in Russian).

DeLellis RA, Lloyd RV, Heitz PU, Eng C, editots. Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours, 3rd edition, Vol 8. Lyon, France: IARC Press; 2004.

Zelinska HV. Cytochemical and immunocytochemical studies of thyroid peroxidase’ expression in preoperative diagnosis of thyroid papillary carcinoma and its radioiodine resistant metastases. Oncology. 2019;21(3):1-6. doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.7925. (in Ukrainian).

Zelinska HV. Cytokeratin 17 and thyroid peroxidase as immunocytochemical markers for preoperative prediction of radioiodine resistance and the effectiveness of radioiodine therapy of papillary thyroid carcinoma. Oncology. 2019;21(1):31-35. doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.7376. (in Ukrainian).

Anderson SR, Mandel S, LiVolsi VA, Gupta PK, Baloch ZW. Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease? Diagn Cytopathol. 2004;31(1):64-7. doi: 10.1002/dc.20075.

Hang JF, Lilo MT, Bishop JA, Ali SZ. Diagnostic Accuracy of Fine Needle Aspiration in Thyroid Nodules Arising in Patients with Graves Disease. Acta Cytol. 2017;61(2):117-124. doi: 10.1159/000464094.

Downloads

Published

2022-06-30

How to Cite

Buldygina, Y., Zelinskaya, A., Zurnadzhy, L., Tarashchenko, Y., Shlyakhtych, S., & Tronko, M. (2022). Morphological features of thyroid benign focal neoplasms in Graves’ disease. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 18(4), 213–218. https://doi.org/10.22141/2224-0721.18.4.2022.1174

Issue

Section

Original Researches

Most read articles by the same author(s)

1 2 3 > >>